Research and Clinical Trials

Title  

Tesaro 3000-PN162-01-001: Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

Brief Description  

To evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Phase 2: Approximately 12 months ] [ Designated as

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Breast - Female

Status  

OPEN

Start Date  

03/20/2017

IRB Number  

Pro00018829

Principal Investigator  

Tan, Antoinette Roslyn

Contact Name  

Audrie Walls

For More Information, Contact  Audrie  , Walls
Phone:  980-442-2386 Fax:    
Email:  Audrie.Walls@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204